Redmile Group LLC Has $13.69 Million Holdings in Establishment Labs Holdings Inc. $ESTA

Key Points

• Redmile Group LLC increased its stake in Establishment Labs Holdings Inc. by 4.8%, now holding 335,366 shares worth approximately $13.7 million, making it the firm's 21st largest position.
• Establishment Labs reported a 12-month revenue growth of 16.1% year over year, despite posting a loss of ($0.57) EPS, which was below analysts' expectations.
• Analysts maintain a consensus rating of "Moderate Buy" for Establishment Labs, with a revised average price target of $56.50, reflecting positive long-term expectations.

Redmile Group LLC lifted its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 4.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 335,366 shares of the company's stock after acquiring an additional 15,217 shares during the quarter. Establishment Labs makes up 1.3% of Redmile Group LLC's portfolio, making the stock its 21st biggest holding. Redmile Group LLC owned 1.16% of Establishment Labs worth $13,685,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ESTA. Quarry LP acquired a new position in shares of Establishment Labs in the fourth quarter worth $27,000. ANTIPODES PARTNERS Ltd bought a new stake in Establishment Labs in the first quarter worth $81,000. Elevation Point Wealth Partners LLC bought a new stake in Establishment Labs in the first quarter worth $207,000. Patriot Financial Group Insurance Agency LLC bought a new stake in Establishment Labs during the first quarter valued at about $234,000. Finally, New York State Common Retirement Fund bought a new stake in Establishment Labs during the first quarter valued at about $894,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Establishment Labs in a research note on Wednesday, August 20th. They issued a "buy" rating and a $60.00 target price for the company. Wall Street Zen lowered shares of Establishment Labs from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. BTIG Research began coverage on shares of Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target for the company. Citigroup boosted their price objective on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research report on Wednesday, July 9th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Establishment Labs in a research report on Friday, June 13th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Establishment Labs currently has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Stock Up 0.9%

NASDAQ:ESTA traded up $0.36 on Friday, hitting $39.03. 173,812 shares of the company's stock were exchanged, compared to its average volume of 392,709. The firm has a 50-day moving average price of $41.41 and a 200-day moving average price of $37.91. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $50.85. The company has a market cap of $1.13 billion, a P/E ratio of -12.80 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The company's revenue was up 16.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. As a group, analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.